FDA Approves First RNA-Targeted Treatment for Rare Hereditary Disease
FDA Greenlights Groundbreaking RNA-Targeted Treatment for Rare Hereditary Disease The U.S. Food and Drug Administration (FDA) granted approval to Dawnzera (donidalorsen) on August 21, 2025. This marks a significant milestone…